NM_016239.4(MYO15A):c.10350+2T>G AND Autosomal recessive nonsyndromic hearing loss 3

Germline classification:: Pathogenic (1 submission)
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV002225025.1

Allele description [Variation Report for NM_016239.4(MYO15A):c.10350+2T>G]

NM_016239.4(MYO15A):c.10350+2T>G

Gene:

MYO15A:myosin XVA [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

17p11.2

Genomic location:

Preferred name:

NM_016239.4(MYO15A):c.10350+2T>G

HGVS:

NC_000017.11:g.18172292T>G
NG_011634.2:g.68587T>G
NM_016239.4:c.10350+2T>GMANE SELECT
NC_000017.10:g.18075606T>G

Links:

dbSNP: rs760148486

NCBI 1000 Genomes Browser:

rs760148486

Molecular consequence:

NM_016239.4:c.10350+2T>G - splice donor variant - [Sequence Ontology: SO:0001575]

Observations:

Condition(s)

Name:: Autosomal recessive nonsyndromic hearing loss 3
Synonyms:: NEUROSENSORY NONSYNDROMIC RECESSIVE DEAFNESS 3; Deafness, autosomal recessive 3
Identifiers:: MONDO: MONDO:0010860; MedGen: C1838263; Orphanet: 90636; OMIM: 600316

Recent activity

Clear Turn Off Turn On

Aster parthianus (52130)
Nucleotide
Multiple myeloma cell lines with acquired resistance to chemotherapeutic agent c...
Multiple myeloma cell lines with acquired resistance to chemotherapeutic agent carfilzomib
Accession: GDS5826

GEO DataSets
Related DataSets for GEO Profiles (Select 131967052) (1)
GEO DataSets

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV001984945	Molecular Diagnosis Center for Deafness	criteria provided, single submitter (ClinGen HL ACMG Specifications v1)	Pathogenic	paternal	clinical testing	PubMed (1) [See all records that cite this PMID]

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV001984945

Molecular Diagnosis Center for Deafness

criteria provided, single submitter

(ClinGen HL ACMG Specifications v1)

Pathogenic

paternal

clinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	paternal	unknown	1	1	not provided	not provided	not provided	clinical testing

Citations

PubMed

Expert specification of the ACMG/AMP variant interpretation guidelines for genetic hearing loss.

Oza AM, DiStefano MT, Hemphill SE, Cushman BJ, Grant AR, Siegert RK, Shen J, Chapin A, Boczek NJ, Schimmenti LA, Murry JB, Hasadsri L, Nara K, Kenna M, Booth KT, Azaiez H, Griffith A, Avraham KB, Kremer H, Rehm HL, Amr SS, Abou Tayoun AN; et al.

Hum Mutat. 2018 Nov;39(11):1593-1613. doi: 10.1002/humu.23630.

PubMed [citation]

PMID:: 30311386
PMCID:: PMC6188673

Details of each submission

From Molecular Diagnosis Center for Deafness, SCV001984945.1

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	1	not provided	not provided	clinical testing	PubMed (1)

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	paternal	unknown	not provided	not provided	not provided		1	not provided	1	not provided

Last Updated: Dec 24, 2023

ClinVar

Relating variation to medicine